GlassScriptPhysician profile
Aisha Mohsin Malik
NPI 1235389537
$5,133.87
in general payments reported to CMS, 2019-2025
46 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $33.03 · 2021: $53.60 · 2023: $910 · 2024: $1,467 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,999.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $726.50 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Ucb, INC. | $399.69 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Abbvie INC. | $361.60 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $296.17 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $280.16 | 2019-2025 | Ultomiris |
| Pfizer INC. | $265.62 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $206.27 | 2019-2025 | Nuplazid |
| Biogen, INC. | $197.19 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Neurocrine Biosciences, INC. | $195.97 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $173.23 | 2023-2025 | Hyqvia |
| Emd Serono, INC. | $151.40 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $150.80 | 2019-2025 | Qelbree |
| Lilly USA, LLC | $138.97 | 2019-2024 | Amyvid |
| Csl Behring | $115.52 | 2019-2025 | Hizentra |
| Ge Healthcare | $96.78 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.